Search Results - "Saoud, J"

A novel clinical trial design to evaluate the efficacy and safety of two exon-skipping PMOs, SRP-4045 and SRP-4053, in patients with Duchenne muscular dystrophy by Laforet, G, Kaye, E, Saoud, J

Get full text

P169 – 2697: A novel clinical trial design to evaluate the efficacy and safety of two exon-skipping drugs, SRP-4045 and SRP-4053, in a master protocol for patients with Duchenne muscular dystrophy (DMD) by Saoud, J, Kaye, E.M, Laforet, G

“…Background DMD, an X-linked myopathy caused by mutations in the DMD gene, results in the inability to produce functional dystrophin, an essential protein for…”
Get full text

Nonclinical pharmacokinetic evaluation of Eteplirsen, SRP-4045, and SRP-4053: Three Phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with Duchenne muscular dystrophy (DMD) by Sazani, P, Charleston, J, Shanks, C, Zhang, J, Carver, M, Saoud, J, Kaye, E

Get full text

G.P.112 by Mendell, J.R, Lowes, L.P, Alfano, L, Saoud, J, Duda, P, Kaye, E

“…DMD is a rare, degenerative, genetic disease that results in progressive muscle loss and premature death and affects 1:5000 male births. Clinically manifest…”
Get full text

PP09.5 – 2350: Pharmacokinetic evaluation of eteplirsen, SRP-4045, and SRP-4053; Three phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with Duchenne muscular dystrophy (DMD) by Sazani, P, Charleston, J.S, Shanks, C, Zhang, J, Carver, M, Saoud, J, Kaye, E.M

“…Background DMD is a rare, X-linked recessive, degenerative neuromuscular disorder caused by mutations in the dystrophin gene. The most prevalent mutations…”
Get full text

On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction by Padma-Nathan, H, McMurray, J G, Pullman, W E, Whitaker, J S, Saoud, J B, Ferguson, K M, Rosen, R C

“…IC351 (Cialis) is a selective inhibitor of PDE5. The efficacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a…”
Get full text

Eteplirsen, a Phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): Clinical update by Kaye, E, Mendell, J, Rodino-Klapac, L, Sahenk, Z, Lowes, L, Alfano, L, Berry, K, Gomez Ramirez, A, Lewis, S, Flanigan, K, Cripe, L, Al-Zaidy, S, Duda, P, Sazani, P, Saoud, J

Get full text

G.O.24 by Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Bird, L, Lowes, L.P, Alfano, L, Gomez, A.M, Lewis, S, Malik, V, Shontz, K, Flanigan, K.M, Shilling, C, Sazani, P, Saoud, J, Duda, P, Kaye, E

“…DMD, a rare, degenerative, genetic disease that results in progressive muscle loss and premature death affects 1:5000 male births. It is caused by deletions in…”
Get full text

PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety by Kaye, E.M, Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Lowes, L.P, Alfano, L, Gomez, A.M, Malik, V, Flanigan, K.M, Shilling, C, Duda, P, Saoud, J

“…Background/Objective DMD, a rare, degenerative, X-linked recessive genetic disease is mostly caused by frame-shift mutations in the dystrophin gene, preventing…”
Get full text

G.P.110 by Sazani, P, Magee, T, Charleston, J.S, Shanks, C, Zhang, J, Carver, M, Rodino-Klapac, L, Sahenk, Z, Roush, K, Bird, L, Lowes, L.P, Alfano, L, Gomez, A.M, Lewis, S, Malik, V, Shontz, K, Flanigan, K, Shilling, C, Bhalli, J, Kaur, H, Walisser, J, Forget, J, Saoud, J, Mendell, J.R, Kaye, E

“…Eteplirsen, SRP-4045 and SRP-4053 are three PMOs developed as treatments for DMD. DMD is mostly caused by mutations in the dystrophin gene that lead to a…”
Get full text

P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD by Mendell, J.R, Rodino-Klapac, L, Sahenk, Z, Roush, K, Bird, L, Lowes, L.P, Alfano, L, Gomez, A.M, Lewis, S, Malik, V, Shontz, K, Flanigan, K.M, Kean, J.R, Allen, H.D, Shilling, C, Sazani, P, Saoud, J, Kaye, E.M

“…DMD is a rare, degenerative, genetic disease that results in progressive muscle loss and premature death. Affecting 1 in 5000 male births, DMD is caused by the…”
Get full text

0504 Efficacy and Safety of Seltorexant in Insomnia Disorder by Savitz, A, Saoud, J B

“…Abstract Introduction Insomnia disorder affects 3-6% of the population and includes functional impairing symptoms for ≥3 months. Current hypnotics have…”
Get full text

Experience with 30 posttraumatic rectourethral fistulas: presentation of posterior transsphincteric anterior rectal wall advancement by al-Ali, M, Kashmoula, D, Saoud, I J

“…We present the challenging problems involving the treatment of rectourethral fistulas, especially those caused by war wounds. Various existing techniques used…”
Get more information

S.09.04 New pharmacological treatments for negative symptoms: pitfalls and future perspectives of clinical trials by Davidson, M., Saoud, J., Staner, C., Luthringer, E., Luthringer, R.

Get full text

Estrogen and androgen influence hypothalamic AVP and CRF concentrations in fetal and adult sheep by Wood, Charles E., Saoud, Christine J., Stoner, Timothy A., Keller-Wood, Maureen

“…The present study tested the hypothesis that action of sex steroids on the hypothalamus–pituitary–adrenal (HPA) axis is measurable in the hypothalamus…”
Get full text

Serotonergic sensitivity in borderline personality disorder: preliminary findings by Hollander, E, Stein, D J, DeCaria, C M, Cohen, L, Saoud, J B, Skodol, A E, Kellman, D, Rosnick, L, Oldham, J M

“…Twelve patients with borderline personality disorder and 15 healthy comparison subjects were challenged with single doses of oral m-chlorophenylpiperazine…”
Get more information

G.P.259 - A novel clinical trial design to evaluate the efficacy and safety of two exon-skipping PMOs, SRP-4045 and SRP-4053, in patients with Duchenne muscular dystrophy by Laforet, G., Kaye, E., Saoud, J.

Get full text

Buspirone in social phobia by Schneier, F R, Saoud, J B, Campeas, R, Fallon, B A, Hollander, E, Coplan, J, Liebowitz, M R

“…The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We…”
Get more information

An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study) by Rusnak, James M., Kopecky, Stephen L., Clements, Ian P., Gibbons, Raymond J., Holland, Anne E., Peterman, Harriet S., Martin, Jenny S., Saoud, Jay B., Feldman, Robert L., Breisblatt, Warren M., Simons, Michael, Gessler, Carl J., Yu, Albert S.

“…Maximal benefits of coronary reperfusion after acute myocardial infarction (AMI) with ST-segment elevation may be attenuated by neutrophil-mediated reperfusion…”
Get full text

Outcome and clinical course in inpatient bulimic women : a 2- to 9-year follow-up study by FALLON, B. A, WALSH, T, SADIK, C, SAOUD, J. B, LUKASIK, C, LUKASIK, V

“…One previous follow-up study suggested that inpatient bulimic women do quite poorly; after an interval of 2 to 5 years, only 13% were recovered. To examine the…”
Get full text